Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer

Abstract

BackgroundPharmaceutical companies in Africa need to invest in both facilities and quality management systems to achieve good manufacturing practice (GMP) compliance. Compliance to international GMP standards is important to the attainment of World Health Organization (WHO) prequalification. However, most of the local pharmaceutical manufacturing companies may be deterred from investing in quality because of many reasons, ranging from financial constraints to technical capacity. This paper primarily evaluates benefits against the cost of investing in GMP, using a Nigerian pharmaceutical company, Chi Pharmaceuticals Limited, as a case study. This paper also discusses how to drive more local manufacturers to invest in quality to attain GMP compliance; and proffers practical recommendations for local manufacturers who would want to invest in quality to meet ethical and regulatory obligations.MethodThe cost benefit of improving the quality of Chi Pharmaceuticals Limited’s facilities and system to attain WHO GMP certification for the production of zinc sulfate 20-mg dispersible tablets was calculated by dividing the annual benefits derived from quality improvement interventions by the annual costs of implementing quality improvement interventions, referred to as a benefit-cost ratio (BCR).ResultCost benefit of obtaining WHO GMP certification for the production of zinc sulfate 20-mg dispersible tablets was 5.3 (95% confidence interval of 5.0–5.5).ConclusionInvestment in quality improvement intervention is cost-beneficial for local manufacturing companies. Governments and regulators in African countries should support pharmaceutical companies striving to invest in quality. Collaboration of local manufacturing companies with global companies will further improve quality. Local pharmaceutical companies should be encouraged to key into development opportunities available for pharmaceutical companies in Africa.

Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study

“…Complying with GMP and assuring quality is an expensive long term and continuously evolving process and requires establishment and maintenance of a QA system. In a highly competitive market where regulatory capacity to oversee and enforce regulations are limited, companies might be tempted to skip certain steps, thereby risking the quality of their products (Milstien et al , 2009; Anyakora et al , 2017).…”

Evaluation of GMP Compliance on Cosmetics: Case Study on Cosmetic Industries in Indonesia

“…(Kurniawati et al, 2021) (Siregar & Andiani, 2019) (Nuraeni, 2019) The decision model to identify and compare the cost and benefit components significance or importance is shown in Figure 1. The cost and benefit parameters were adapted from research conducted by Anyakora et al (2017), with adjustments to operational activities stated in Regulation of Indonesian FDA 31/2020 concerning guidelines for GMP on cosmetics (CPKB), in which these activities have the potential costs incurred. The components of major cost and major benefit coded as in Figure 1 are detailed in Table 1.…”

Good manufacturing practice in low‐ and middle‐income countries: Challenges and solutions for compliance

“…LMICs may leverage WHO GMP compliance requirements to both improve medicine safety and expand the market of local pharmaceutical manufacturers. For example, certain manufacturers in Nigeria have achieved WHO GMP certification, leading to their products being marketed internationally [15]. Although these solutions may have initial resourcing implications (e.g.…”